CN102802617B - 用于稳定的液体药物制剂的方法和组合物 - Google Patents

用于稳定的液体药物制剂的方法和组合物 Download PDF

Info

Publication number
CN102802617B
CN102802617B CN201080064175.9A CN201080064175A CN102802617B CN 102802617 B CN102802617 B CN 102802617B CN 201080064175 A CN201080064175 A CN 201080064175A CN 102802617 B CN102802617 B CN 102802617B
Authority
CN
China
Prior art keywords
protein
composition
pharmaceutically active
active compound
liquid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201080064175.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN102802617A (zh
Inventor
H.J.莱顿
C.J.弗兰加基斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Exodos Life Sciences LP
Original Assignee
Exodos Life Sciences LP
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exodos Life Sciences LP filed Critical Exodos Life Sciences LP
Publication of CN102802617A publication Critical patent/CN102802617A/zh
Application granted granted Critical
Publication of CN102802617B publication Critical patent/CN102802617B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6435—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a connective tissue peptide, e.g. collagen, fibronectin or gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/644—Transferrin, e.g. a lactoferrin or ovotransferrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1658—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5089—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Immunology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201080064175.9A 2009-12-18 2010-12-17 用于稳定的液体药物制剂的方法和组合物 Expired - Fee Related CN102802617B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28798809P 2009-12-18 2009-12-18
US61/287988 2009-12-18
PCT/US2010/061135 WO2011075691A1 (en) 2009-12-18 2010-12-17 Methods and compositions for stable liquid drug formulations

Publications (2)

Publication Number Publication Date
CN102802617A CN102802617A (zh) 2012-11-28
CN102802617B true CN102802617B (zh) 2016-05-11

Family

ID=44167729

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201080064175.9A Expired - Fee Related CN102802617B (zh) 2009-12-18 2010-12-17 用于稳定的液体药物制剂的方法和组合物

Country Status (10)

Country Link
US (2) US9629920B2 (enExample)
EP (1) EP2512460A4 (enExample)
JP (2) JP2013515004A (enExample)
CN (1) CN102802617B (enExample)
AU (1) AU2010330750B2 (enExample)
BR (1) BR112012014962A2 (enExample)
CA (1) CA2784826A1 (enExample)
IL (1) IL220465A (enExample)
RU (1) RU2589697C2 (enExample)
WO (1) WO2011075691A1 (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013204801B2 (en) 2012-05-23 2014-11-06 Omniblend Innovation Pty Ltd Composition and method for management of diabetes or pre-diabetes
JP6223444B2 (ja) * 2012-07-05 2017-11-01 ザ リサーチ ファウンデイション フォー ザ ステイト ユニバーシティー オブ ニューヨーク 蛋白質‐脂質複合体を用いた抗生物質治療の増強
CN113384373B (zh) * 2013-11-05 2022-10-21 辛纳吉勒公司 经由口腔进行连续药物递送的装置和方法
PT2838510T (pt) 2013-11-08 2016-11-23 Lilly Co Eli Solução de atomoxetina
WO2016089893A1 (en) 2014-12-01 2016-06-09 Achelios Therapeutics Inc. Methods and compositions for treating migraine and conditions associated with pain
CN113197851A (zh) 2015-05-06 2021-08-03 辛纳吉勒公司 包含药物粒子的药用悬浮液、用于其配给的装置、以及其使用方法
KR20250047404A (ko) * 2015-12-08 2025-04-03 바이오매트리카 인코포레이티드 적혈구 침강 속도의 감소
CN106199007B (zh) * 2016-08-03 2017-04-05 烟台普罗吉生物科技发展有限公司 蛋白保护剂
CN115813888A (zh) 2016-12-20 2023-03-21 罗曼治疗系统股份公司 包含阿塞那平的透皮治疗系统
EP3558276B1 (en) 2016-12-20 2024-11-06 LTS Lohmann Therapie-Systeme AG Transdermal therapeutic system containing asenapine and polysiloxane or polyisobutylene
WO2019002204A1 (en) 2017-06-26 2019-01-03 Lts Lohmann Therapie-Systeme Ag TRANSDERMAL THERAPEUTIC SYSTEM CONTAINING ASENAPINE AND SILICONE-TYPE ACRYLIC HYBRID POLYMER
WO2019038584A1 (en) * 2017-08-19 2019-02-28 Ftf Pharma Private Limited An oral pharmaceutical composition comprising zonisamide and process of preparation thereof
AU2018333058A1 (en) * 2017-09-15 2020-03-12 Gojo Industries, Inc. Antimicrobial composition
AU2019291060B2 (en) 2018-06-20 2024-09-05 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine
US12329862B2 (en) 2018-06-20 2025-06-17 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine
CN109212176B (zh) * 2018-08-30 2019-10-11 中拓生物有限公司 一种丙酮酸测定试剂盒及其制备方法和应用
JP7653352B2 (ja) * 2018-09-05 2025-03-28 エクスプレステック、リミテッド、ライアビリティ、カンパニー 免疫グロブリンａ製剤
US11413275B1 (en) 2018-12-14 2022-08-16 ECI Pharmaceuticals, LLC Oral liquid compositions including valsartan
US10478422B1 (en) 2018-12-14 2019-11-19 ECI Pharmaceuticals, LLC Oral liquid compositions including valsartan
US11446243B1 (en) * 2019-08-05 2022-09-20 ECI Pharmaceuticals, LLC Oral liquid compositions including valsartan
WO2022103639A1 (en) 2020-11-16 2022-05-19 Orcosa Inc. Methods of treating autoimmune or inflammatory conditions with cannabidiol or its derivatives/analogs
US11672761B2 (en) 2020-11-16 2023-06-13 Orcosa Inc. Rapidly infusing platform and compositions for therapeutic treatment in humans
US11452690B1 (en) 2021-01-27 2022-09-27 ECI Pharmaceuticals, LLC Oral liquid compositions comprising amlodipine besylate and methods of using the same
CN113384526A (zh) * 2021-08-03 2021-09-14 合肥医工医药股份有限公司 一种稳定的阿哌沙班口服溶液制剂及其制备方法
CN117398380A (zh) * 2022-06-29 2024-01-16 威智医药股份有限公司 卡维地洛或其盐、组合物的新用途及该组合物和制备方法
WO2025068937A1 (en) * 2023-09-30 2025-04-03 Liqmeds Worldwide Limited An oral liquid formulation of metoprolol
AU2024352372A1 (en) * 2023-09-30 2026-04-09 Liqmeds Worldwide Limited An oral liquid formulation of metoprolol
CN119112774A (zh) * 2024-09-23 2024-12-13 石家庄四药有限公司 一种利奈唑胺氯化钠注射液及其制备方法
US12605388B2 (en) 2024-09-25 2026-04-21 Azurity Pharmaceuticals Ireland Limited Lamotrigine salts, co-crystals, and compositions
CN120000598B (zh) * 2025-03-27 2025-10-10 广东立国制药有限公司 一种头孢呋辛酯直压颗粒及其制备工艺

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1270529A (zh) * 1997-09-18 2000-10-18 人类Rt·公司 含血浆蛋白的药物组合物

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61271226A (ja) * 1985-05-24 1986-12-01 Chemo Sero Therapeut Res Inst 利尿剤
JPS63215640A (ja) * 1987-03-04 1988-09-08 Nippon Hai Potsukusu:Kk 易吸収性抗炎症剤及びその製造方法
US5051406A (en) * 1987-03-04 1991-09-24 Nippon Hypox Laboratories Incorporated Pharmaceutical composition using albumin as a carrier and process for producing the same
JPH05238947A (ja) * 1992-02-28 1993-09-17 Yakult Honsha Co Ltd 細菌毒素中和剤
ATE236657T1 (de) 1997-05-09 2003-04-15 Deutsches Krebsforsch Konjugat, umfassend einen folsäureantagonisten und einen träger
PT1023050E (pt) 1997-06-27 2013-12-04 Abraxis Bioscience Llc Novas formulações de agentes farmacológicos, métodos para a sua preparação e métodos para a sua utilização
JPH11258236A (ja) * 1998-03-09 1999-09-24 Sekisui Chem Co Ltd 抗リン脂質抗体測定試薬
CA2362338A1 (en) * 1998-07-30 2000-02-10 Human Rt. Pharmaceutically acceptable composition comprising an aqueous solution of paclitaxel and albumin
PL197812B1 (pl) 1999-07-09 2008-04-30 Ortho Mcneil Pharm Inc Doustne ciekłe kompozycje farmaceutyczne maskujące smak
CA2509365C (en) 2002-12-09 2012-08-07 American Bioscience, Inc. Compositions and methods of delivery of pharmacological agents
ES2383300T3 (es) 2003-11-13 2012-06-20 Hanmi Holdings Co., Ltd Fragmento Fc de IgG para un vehículo de fármacos y procedimiento para su preparación
US20050266031A1 (en) 2004-05-25 2005-12-01 Jay Dickerson Pharmaceutical suspension composition
TW200607523A (en) 2004-06-01 2006-03-01 Domantis Ltd Drug compositions, fusions and conjugates
DE102004057196A1 (de) 2004-11-26 2006-06-01 Rösner Research GmbH & Co.KG Verfahren zur Herstellung von Albumin-Konjugaten mit Nicht-steroidalen Antirheumatika (NSAR)
EA015277B1 (ru) 2008-04-22 2011-06-30 Государственное Научное Учреждение "Институт Биоорганической Химии Национальной Академии Наук Беларуси" Конъюгат 28-норбрассинолида с бычьим сывороточным альбумином в качестве иммуногена
US20130109674A1 (en) 2009-12-18 2013-05-02 Achelios Therapeutics Llc Methods and compositions for treating and preventing trigeminal autonomic cephalgias, migraine, and vascular conditions
JP5944325B2 (ja) 2009-12-18 2016-07-05 エクソドス ライフ サイエンシーズ リミテッド パートナーシップ 皮膚の炎症を治療するための方法及び組成物
CA2784788A1 (en) 2009-12-18 2011-06-23 Exodos Life Sciences Limited Partnership Methods and compositions for treating peripheral vascular disease

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1270529A (zh) * 1997-09-18 2000-10-18 人类Rt·公司 含血浆蛋白的药物组合物

Also Published As

Publication number Publication date
JP2013515004A (ja) 2013-05-02
EP2512460A4 (en) 2015-01-21
US20170224834A1 (en) 2017-08-10
US20130071412A1 (en) 2013-03-21
IL220465A (en) 2017-03-30
WO2011075691A1 (en) 2011-06-23
IL220465A0 (en) 2012-08-30
AU2010330750B2 (en) 2015-10-01
CA2784826A1 (en) 2011-06-23
AU2010330750A1 (en) 2012-08-02
CN102802617A (zh) 2012-11-28
RU2589697C2 (ru) 2016-07-10
US9629920B2 (en) 2017-04-25
EP2512460A1 (en) 2012-10-24
RU2012130391A (ru) 2014-01-27
JP2016053038A (ja) 2016-04-14
BR112012014962A2 (pt) 2016-04-05

Similar Documents

Publication Publication Date Title
CN102802617B (zh) 用于稳定的液体药物制剂的方法和组合物
ES2731601T3 (es) Composiciones de dosificación oral de liberación retardada que contienen CDDO-Me amorfo
KR101170840B1 (ko) 남용 방지성 암페타민 화합물
JP2002504519A (ja) 新規なペプチド共重合体組成物
US20050080012A1 (en) Sustained release pharmaceutical compounds to prevent abuse of controlled substances
JP2009533443A (ja) 一置換及び二置換のオキシコドン化合物及び組成物
CN103347532A (zh) 口服可生物利用肽药物组合物及其方法
JP2009533459A (ja) 共有結合する化合物の鎮痛作用の増強と、有害な副作用の減衰と、前記化合物の乱用の予防とのための組成物及び方法
TW200302734A (en) Pharmaceutical compositions for hepatitis c viral protease inhibitors
JPH09508141A (ja) ビタミンｂ▲下１２▼とタンパク質との複合体
CN101631566A (zh) 苯丙胺与其它兴奋剂的极性亲水性前体药物及其制造和使用方法
JP6482570B2 (ja) 経皮吸収促進剤及び経皮吸収促進助剤
JP2002502825A (ja) 経口運搬用共重合体組成物
US20220280645A1 (en) Pharmaceutical Eutectic Salt Formation
CN111278466A (zh) 伊马替尼的液体剂型
US20190307886A1 (en) A co-amorphous form of a substance and a protein
US20150031632A1 (en) Orally Disintegrating Compositions of Linaclotide
JP2025134793A (ja) 微粒子化薬物レジネートをベースにした医薬組成物及びその調製方法
CN114469902A (zh) 雷沙吉兰或其药用盐舌下膜剂及其制备方法、应用
PT1494649E (pt) Formulações de megestrol em nanopartículas
CN110384803B (zh) 一种大环主体分子作为药物增溶剂的应用
CN112022833A (zh) 一种恩杂鲁胺药物组合物及其制备方法
WO2025043394A1 (zh) 形成超分子自组装复合体的试剂盒及其应用
CN100413533C (zh) 一种防止管制物质滥用的持续释放的药学化合物
WO2026080937A1 (en) Novel therapeutic radiopharmaceuticals and methods

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20160511

Termination date: 20191217

CF01 Termination of patent right due to non-payment of annual fee